Reply  by O’Keefe, James H. et al.
The Optimal Low-Density
Lipoprotein Is 50 to 70 mg/dl
It was with great delight that I read the report by O’Keefe et al. (1)
in a recent issue of the Journal. It provides scientific support to my
practice decisions over the last six years. I have been treating
virtually all of my patients over 40 years of age to reduce their
low-density lipoprotein (LDL) cholesterol to 2.0 mmol/l (77
mg/dl) with a target of 1.5 mmol/l (58 mg/dl).
I am a general practitioner in Sudbury, Ontario, which is a
cardiovascular “hotspot” owing both to the genetics in the Fran-
cophone population, and our high rate of smoking and obesity.
The average age of my patients is in the 60s. At last count, I had
186 patients with type II diabetes, and the usual number of
smokers, hypertensive, sedentary life-style and obese patients;
overall, a higher than average risk practice.
Since reading in 1998 that the average myocardial infarction
(MI) patient in our part of Canada has only 1.8 cardiovascular risk
factors, it has become quite clear to me that the only common
denominator in an acute coronary syndrome (ACS), or thrombotic
cerebral vascular accident (CVA), in my practice was an LDL of
2.0.
Hence, I have been very aggressive with LDL lowering in my
patient group. As a consequence, the rate of MIs in my 3000-
patient general practice has gone from 50 to 60 per year to 2 per
year. I have had only a single ACS in my treated and compliant
populace since 1998. This was in a woman with six of seven coronary
heart disease risk factors; she began treatment in December 2000
and suffered (and survived) an ACS three months later. In the
same period of time, I have had eight other ACS events in patients
and one thrombotic CVA, all of which were in noncompliant
patients.
It has been my practice to screen all patients over age 40 and
patients in their 30s with significant family history of premature
MI or a significant number of risk factors. My impression is that
there is a “cut-off” level of the LDL below which the atheroscle-
rotic process is halted, and indeed reversed by the documented
function of high-density lipoprotein (HDL) in reabsorbing estab-
lished plaque. It seems as though LDL is a necessary ingredient in
the atherosclerotic process, in whose absence the other cardiovas-
cular risk factors are unable to exert influence in accelerating the
process.
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REPLY
We thank Dr. Clendenning for his interest in our study (1). Dr.
Clendenning’s suggestion that the systematic treatment of his
patients to a low-density lipoprotein (LDL) cholesterol target of
2.0 mmol/l (77 mg/dl) over the past four years has markedly
reduced cardiovascular event rate in his practice is fascinating and
consistent with the hypothesis of our study. Several other physi-
cians have communicated similar experiences to us that provide
anecdotal support for the concept that the optimal LDL range for
patients at risk for cardiovascular event is 50 to 70 mg/dl. One solo
practitioner cardiologist from Idaho who has employed a similar
strategy targeting the LDL to 70 mg/dl as part of a multimodal
risk-factor intervention recently decided to stop performing per-
cutaneous coronary interventions because he believed his volume of
procedures has dropped too low to maintain adequate skills.
Aggressive LDL lowering has been shown to improve prognosis
even in patients without coronary heart disease (CHD) who have
average LDL levels at baseline, but who have CHD risks such as
hypertension (2), diabetes (3), or low HDL cholesterol levels (4).
This accumulating evidence suggests that achieving these lower
LDL targets will improve CHD prognosis for many of our
patients.
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World Trade Center Attack
and Cardiac Events: Fact or Fear?
The Journal recently published two studies suggesting a specific
increase in the number of ventricular arrhythmias in implantable
defibrillator patients in the weeks following the World Trade
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